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Abstract: Spirotetronate and spirotetramate natural products include a multitude of compounds with potent antimicrobial and antitumor 
activities. Their biosynthesis incorporates many unusual biocatalytic steps, including regio- and stereo-specific modifications, cyclizations 
promoted by Diels-Alderases, and acetylation-elimination reactions. Here we focus on the intriguing acetate elimination catalyzed by 
AbyA5, implicated in formation of the key Diels-Alder substrate to give the spirocyclic system of the antibiotic abyssomicin C. Using 
synthetic substrate analogues we show that AbyA5 catalyzes stereospecific acetate elimination, establishing the (R)-tetronate acetate as 
a biosynthetic intermediate. The X-ray crystal structure of AbyA5, the first of an acetate eliminating enzyme, reveals a deviant acetyl 
esterase fold. Molecular dynamics simulations and enzyme assays demonstrate use of a His-Ser dyad to catalyze either elimination or 
hydrolysis, via disparate mechanisms, under substrate control.  
  
Acetylation is a ubiquitous chemical modification of major importance in biology. Acetylation state impacts protein stability, folding 
and localization, central metabolism, apoptosis, transcription, cytoskeletal organisation, circadian regulation, bacterial cell wall 
architecture and integrity, natural product bioactivity, and antimicrobial resistance amongst others.[1] The addition or removal of 
acetyl groups is facilitated by the coordinated action of acetylases and deacetylases, which function within stringently regulated 
cellular networks.[2] Deacetylases have been the subject of considerable detailed investigation, and have been shown, without 
exception, to catalyze hydrolysis of the acetate via attack on the carbonyl group.[3] Recently, studies of spirotetronate and 
spirotetramate biosynthetic pathways have revealed an alternative biocatalytic route to the processing of acetylated molecules. 
This involves the action of free-standing acetate lyases; enzymes which employ a hitherto uncharacterized mechanism to 
eliminate acetate with formation of a double bond (Scheme 1).[4] These enzymes are unique to spirotetronate/spirotetramate 
pathways, sharing <20% sequence identity to any protein of known structure. Given the role of acetate lyases in the biosynthesis 
of natural products of outstanding clinical potential, their enigmatic enzymology, and their potential utility as industrially relevant 
biocatalysts, these enzymes represent intriguing and important targets for detailed study.  To elucidate the mechanistic details of 
enzyme catalyzed acetate elimination we focused on the putative acetate lyase AbyA5 from the abyssomicin C biosynthetic 
pathway. The antimicrobial natural product abyssomicin C (1) is a potent inhibitor of bacterial folate metabolism effective against 
a multitude of Gram-positive pathogens including Mycobacterium tuberculosis and multi-drug resistant strains of Staphylococcus 
aureus.[5] The biosynthetic pathway to this compound, which comprises a multi-modular polyketide synthase (PKS) and associated 
tailoring and regulatory proteins, is encoded for within a single gene cluster (aby) spanning ~60 kb of the genome of the marine 
actinomycete Verrucosispora maris AB-18-032.[6] Based on feeding studies, chemotyping of V. maris gene knock-out mutants, 
comparative bioinformatics analyses, and in vitro studies of homologous enzymes from other spirotetronate and spirotetramate 
pathways, a general mechanism for the biosynthesis of abyssomicin C has been proposed (Figure S1).[7] One of the most intriguing 
features of this pathway is the formation and subsequent tailoring of the tetronate ring containing compound 2, via the acetylated 
intermediate 3, to yield 4, which subsequently serves as a substrate for a Diels-Alderase catalyzed intramolecular [4 + 2] 
cycloaddition reaction (Figure 1).[8] The conversion of 3 to 4 is postulated to proceed via elimination of acetate, yielding the 14,15-
exocyclic double bond, but it is not known which enantiomer of 3 is involved. The introduction of this dienophile is implicitly required 
for the subsequent AbyU catalyzed cycloaddition reaction that forms the heterobicyclic ring nucleus of abyssomicin C. Amino acid 
sequence alignments of the known spirotetronate/spirotetramate acetate lyases Agg5 (agglomerin)[4b] and QmnD4 
(quartromicin),[9b] and putative acetate eliminating enzymes from related biosynthetic pathways, with Open Reading Frames within 
the aby cluster, identify AbyA5 as the likely eliminating enzyme from the abyssomicin C pathway (Figure S2). To ascertain whether 
AbyA5 does indeed catalyze acetate elimination, this enzyme was recombinantly over-expressed in E. coli BL21(DE3) cells and 
purified to homogeneity (Figure S3). Recombinant AbyA5 was found to be a monomeric, well-folded, mono-disperse species in 
solution.  
Both enantiomers of the unnatural substrate analogues of acetate 3 were synthesized. Hydroxy ester 5 was readily prepared 
from D-mannitol diacetonide in 4 steps according to the literature.[9] Coupling with β-ketothioester 6 in the presence of 
CF3CO2Ag gave keto ester 7 in 79% yield. The key TBAF mediated Dieckmann cyclization has wide precedent in the literature, 
however, difficulty has been reported using this method.[10] In our hands this reaction proved challenging until the purified 
compound was washed with 1 M HCl according to Osada et. al.[11] Following the cyclization the primary alcohol 8 was 
acetylated to give desired (R)-analogue (R)-9. To prepare a standard of the elimination product 10 for the enzyme assays, 
  
acetate (R)-9 was reacted with DBU giving alkene 10, other bases (eg. TBAF, imidazole and triethylamine) gave no reaction. 
An alternative approach to the synthesis of 10 is from 11 as shown in Scheme 2.  
Incubation of (R)-acetate (R)-9 with recombinant AbyA5 in vitro yielded a single product with a mass (m/z [M-H]- = 237) and 
1H-NMR in keeping with alkene 10, and consistent with the authentic synthetic standard (Figures 2 and S4), confirming that 
elimination had taken place. Control reactions lacking enzyme, or containing heat denatured AbyA5, showed no evidence of 
product formation. AbyA5 showed no activity against the (S)-enantiomer (S)-9, demonstrating that the enzyme is stereospecific 
for the (R)-form only. Steady-state kinetic characterization of AbyA5 with (R)-9, employing a spectrophotometric assay 
(supplementary information), yielded kcat= 1.8 ± 0.13 min-1, Km= 27 ± 8.4 μM, and kcat/Km= 0.072 ± 0.021 min-1μM (Figure 2). 
Together these data demonstrate the eliminating activity of AbyA5, unambiguously establish the role of this enzyme in 
abyssomicin C biosynthesis, and reveal that this reaction proceeds in a stereospecific manner. To provide a structural 
framework of the AbyA5 catalyzed elimination reaction we determined the X-ray crystal structure of the enzyme. This was 
achieved using the single wavelength anomalous dispersion (SAD) method, to 2.3 Å resolution, employing a selenomethinone 
labeled quadruple point mutant of AbyA5, within which the residues Leu66, Leu158, Leu195 and Leu295 were mutated to 
methionines (supplementary information). This structure was subsequently used as a molecular replacement search model to 
determine that of wild type AbyA5 to 2.5 Å resolution. The structure of AbyA5 is consistent with a monomeric α/β hydrolase 
(ABH), possessing a central, largely parallel 8-stranded β-sheet surrounded by α-helices (Figure 3). As with other ABHs, the 
second strand within the β-sheet runs antiparallel to the remaining 7 and the sheet possesses a left handed super-helical twist. 
The major structural features that distinguish AbyA5 from other ABHs are the large number of helices that decorate the central 
β-sheet core of the enzyme (15 in total) and the presence of a 4-helix subdomain that extends outwards from the top of AbyA5 
in a fashion analogous to that reported in 2,6-dihydroxy-pseudo-oxynicotine hydrolase.[12] Structurally, AbyA5 is most closely 
related to members of the acetyl esterase family of deacetylases, despite minimal amino acid sequence identity (<20%). 
Inspection of the AbyA5 crystal structure and superposition with structurally related acetyl esterases unambiguously identifies 
the location of the enzyme active site, which sits within an extended cleft on the surface of the enzyme of ~40 Å in length and 
~10 Å in depth. The left side of the cleft houses a canonical ABH catalytic triad, comprised of the residues Ser198, Asp285 
and His312 (Figure 3). Ser198 is located on a nucleophilic elbow formed by a loop linking β5 and α7. His312 sits on the 
opposite side of Ser198, on a loop between β8 and α14, directly above Asp285. To further investigate the acetyl elimination 
by AbyA5, a modelling study was performed. Molecular docking was conducted using the AbyA5 crystal structure with both 
(R)-3 and (S)-3. This yielded a series of closely related models of the AbyA5-substrate complex, each of which positions the 
substrate directly within the AbyA5 active site cleft and locates the acetyl group in close proximity to Ser198 and His312 
(Figure 3). The side chain of 3 occupies a largely hydrophobic portion on the right of the active site cleft. Given the minimal 
number of contacts between AbyA5 and substrate in this region it appears unlikely that chain length and composition is a 
major determinant of substrate selectivity. This is consistent with our in vitro assay data, which demonstrate that the substrate 
analogue (R)-9, which lacks the side chain functional group decoration of 3, is readily acted upon by the enzyme. In contrast, 
appropriate positioning of the acetylated tetronate ring within the active site appears to play a significant role in substrate 
binding. This is achieved by a combination of shape and charge complementarity between the acetylated ring and the active 
site cavity, supported by a several hydrogen bonds. The point mutants AbyA5_H321A and Ser198A showed no activity with 
(R)-9, despite both proteins being well folded monodisperse species in solution (Figure S5), implying a critical role for these 
  
residues in substrate positioning and/or catalysis within the active site. Molecular dynamics simulations using docked poses 
of (R)-3 reveal a distance of ~3.5 Å between His312 and C15 of the substrate, optimal for proton abstraction and consistent 
with the His dependent catalytic mechanism proposed previously for QmnD4 (Figure S6).[9b] The distance between His312 
and C15 for (S)-3 docked poses is >4.5 Å, sufficient to preclude proton abstraction and thereby negate catalysis (Figure 3). 
Together, these data offer an explanation for the stereoselectivity of AbyA5 observed our in vitro enzyme assays.  
The crystal structure of AbyA5 raises the intriguing possibility that this protein scaffold could support both acetate 
elimination and hydrolysis, though no (R)-9 hydrolytic product was detected in our functional assays. To test this hypothesis 
the ability of AbyA5 to deacetylate p-nitrophenolacetate (p-NPA) in vitro was monitored spectrophotometrically.[13] AbyA5 
was found to catalyze the hydrolytic deacetylation of p-NPA, with kcat= 44 ± 2.4 min-1, Km= 78 ± 9.2 μM, and kcat/Km= 0.62 ± 
0.31 min-1μM (Figure S7). Molecular dynamics simulations of AbyA5 in the absence of substrate reveal appropriate 
positioning of the His-Ser-Asp triad, as defined by the occupation of hydrogen bonds between these side chains, for ~10% of 
the simulation duration, consistent with the ability of the enzyme to catalyze ester bond cleavage via a canonical acetyl 
esterase mechanism (Figure S8).[14] The infrequent adoption of this catalytically competent state accounts for the 
comparatively poor catalytic efficiency of AbyA5 for p-NPA as compared to naturally evolved acetyl esterases, with an up to 
60 fold lower kcat/Km (Table S2). Neither AbyA5_H321A nor Ser198A showed any activity with p-NPA. Docking studies 
confirmed that p-NPA can be readily accommodated within the AbyA5 active site. In summary, we report the structural and 
functional characterization of the acetate lyase AbyA5, revealing the molecular details of the acetate elimination reaction 
catalyzed by this enzyme, and in doing so, establish explicitly the role of this biocatalyst in abyssomicin C biosynthesis. 
AbyA5 is shown to possess an acetyl esterase like fold, within which conserved catalytic machinery can be deployed to 
facilitate either acetate elimination or ester hydrolysis, in a manner dictated by substrate identity. Our studies establish the 
origins of substrate selectivity in AbyA5, revealing absolute stereoselectivity for the (R)-tetronate, but relaxed selectivity for 
the C3 chain. These findings hint at the potential general utility of AbyA5 as an acetate elimination biocatalyst. Although 
evolutionarily selected to catalyze elimination, AbyA5 exhibits kinetic parameters for ester hydrolysis comparable to naturally 
evolved acetyl esterases. Catalytic multifunctionality is an inherent feature of many biocatalysts, however; AbyA5 is unusual 
in its proficiency in performing a secondary non-cognate reaction.[15] Our studies also further expand the breadth of 
transformations catalyzed by α/β-hydrolase fold enzymes, highlighting the utility of this protein scaffold in supporting a 
diverse array of biocatalytic reactions. Finally, given the high degree of sequence identify between AbyA5 and acetate 
eliminating enzymes from other spirotetronate/spirotetramate pathways, we conclude that many of the key findings reported 
herein will be directly applicable to acetate lyases from other biosynthetic pathways. 
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Scheme 1. Enzyme catalyzed deacetylation and acetate elimination. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Tetronate ring formation and tailoring during abyssomicin C biosynthesis. 
 
 
 
 
 
 
 
 
 
 
  
Scheme 2. Synthesis of acetate elimination precursor (R)-9 and product 10. MS = molecular sieve, THF = tetrahydrofuran, 
TBAF = tetrabutylammonium fluoride, DMAP = 4-(dimethylamino)pyridine, DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene, LDA = 
lithium diisopropylamide, DMP = Dess-Martin periodinane, DMSO = dimethylsulfoxide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Acetate eliminating activity of AbyA5. a) Synthesized substrate analogues (R)-9 and (S)-9 and alkene 10. b) HPLC-MS 
demonstrating the AbyA5 catalyzed conversion of (R)-9 to 10 by AbyA5. c) Steady-state kinetic characterization of the conversion of 
(R)-9 to 10. Error bars are standard errors from the mean calculated from reactions run in triplicate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 3. Crystal structure of AbyA5. a) Overall fold of the AbyA5 monomer showing the catalytic domain (blue) and 4 helix 
capping domain (yellow). S, Ser198; D, Asp 285; H, H312; b) Active site cleft on the enzyme surface (red). The capping 
domain has been removed for clarity. Asp285 is obscured by His312. c) Model of (R)-3 and (S)-3 docked into the active site 
of AbyA5.  
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1. Supplementary	Methods	
1.1. Gene	cloning	
The	abyA5	 gene	 was	 amplified	 from	Verrucosispora	 maris	AB-18-032	 genomic	 DNA	 by	
polymerase	 chain	 reaction	 (PCR)	 using	 the	 primers	 5’-
GGTATTGAGGGTCGCATGatgagcaacgacgtcgcaga-3’	 (forward)	 and	 5’-
AGAGGAGAGTTAGAGCCTTAcgcccgtcctccctc-3’.	Overlap	sequences	 (underlined)	were	added	
to	 allow	 for	 directional,	 ligation-independent	 cloning.	 Purified	abyA5	 PCR	 products	 were	
cloned	 into	pre-linearised	pET-30	Xa/LIC	 (Novagen)	 following	 the	manufacturer’s	 protocol.	
The	 resulting	 construct,	abyA5::pET30,	 encodes	 an	N-terminally	 hexa-histidine/S-tagged	
variant	 of	 AbyA5.	 Gene	 encoding	 the	 AbyA5	 mutants	 H312A,	 Ser198A	 and	
L66M/L158M/L195M/L295M	(AbyA5_QM)	were	amplified	by	PCR	from	commercially	sourced	
plasmids	 containing	 synthetic	 genes	 encoding	 each	 mutant	 (MWG	 EurofinsTM),	 using	 the	
primers	 5’-AAGTTCTGTTTCAGGGCCCGATGAGCAACGATGTCGCAGAG-3’	 (forward)	 and	 5’-
ATGGTCTAGAAAGCTTTATCACGCACGACCGCCTTCCAC-3’	 (reverse),	 introducing	 appropriate	
overlap	sequences	(underlined)	for	insertion	into	the	plasmid	pOPINF,1	pre-cut	with	KpnI	and	
HindIII.	Ligations	were	carried	out	using	the	 In-Fusion	cloning	kit	 (Clonetech).	The	resulting	
constructs,	abyA5_H312A::pOPINF,		abyA5_S198A::pOPINF	and	abyA5_QM::pOPINF	encode	
an	 N-terminally	 hexa-histidine	 tagged	 variants	 of	 AbyA5_H312A,	 AbyA5_Ser198A	 and	
AbyA5_QM.	 The	 sequences	 of	 all	 plasmids	 were	 verified	 by	 DNA	 sequencing	 prior	 to	
transformation	 into	 Escherichia	 coli	 BL21	 (DE3)	 or	 E.	 coli	 B834	 (DE3)	 cells	 for	 protein	
expression.	
	
1.2. Protein	expression	and	purification	
Wild	type	AbyA5,	AbyA5_H312A,	and		AbyA5_Ser198A	were	expressed	as	follows.	100	mL	of	
LB	medium	supplemented	with	kanamycin	(50	μg/mL)	was	inoculated	with	a	single	colony	of	
E.	 coli	 BL21	 (DE3)	 pre-transformed	 with	 abyA5::pET30,	 abyA5_H312A::pOPINF,	 or	
abyA5_S198A::pOPINF.	Cultures	was	incubated	overnight	with	shaking	(200	rpm)	at	37	°C	and	
were	each	used	 to	 inoculate	1	 L	of	 LB	medium	supplemented	with	kanamycin	 (50	μg/ml).	
Cultures	was	incubated	with	shaking	(200	rpm)	at	37	°C	until	the	optical	density	at	600	nm	
reached	0.6-0.8,	at	which	point	protein	expression	was	induced	by	the	addition	of	IPTG	to	a	
final	concentration	of	1	mM.	Cultures	were	further	incubated	with	shaking	(200	rpm)	for	16	
hrs	 at	 20	 °C,	 following	 which	 the	 cells	 were	 harvested	 by	 centrifugation,	 supernatants	
removed,	and	resulting	cell	pellet	stored	at	-80	°C.		
Selenomethionine	 substituted	 wild	 type	 AbyA5	 was	 expressed	 as	 follows.	 100	 mL	 of	 LB	
	 3	
medium	supplemented	with	kanamycin	(50	μg/mL)	was	inoculated	with	a	single	colony	of	E.	
coli	B834	(DE3)	pre-transformed	with	abyA5::pET30.	The	culture	was	incubated	overnight	with	
shaking	 (200	 rpm)	 at	 37	 °C	 before	 being	 clarified	 by	 centrifugation.	 The	 supernatant	 was	
discarded	and	the	resulting	pellet	was	resuspended	in	100	mL	of	fresh	LB	medium,	which	was	
in-turn	used	to	inoculate	1	L	of	M9	medium	(preheated	to	37	°C	and	aerated	by	shaking	at	200	
rpm	for	2	hrs),	supplemented	with	SeMet	vitamin	mix	(Molecular	dimensions)	and	kanamycin	
(50	μg/mL).	The	culture	was	incubated	at	37	°C	with	shaking	(200	rpm)	until	the	optical	density	
at	 600	 nm	 reached	 0.8-1.2.	 The	 culture	 was	 then	 supplemented	 with	 150	 mg	 of	
selenomethionine	(Sigma-Aldrich)	and	further	incubated	at	37	°C	with	shaking	at	200	rpm	for	
30	minutes,	at	which	point	protein	expression	was	induced	by	the	addition	of	IPTG	to	a	final	
concentration	of	1	mM.	This	culture	was	then	incubated	with	shaking	(200	rpm)	at	37	°C	for	
16	hrs,	centrifuged,	the	supernatant	removed,	and	the	resulting	cell	pellet	stored	at	-80	°C.	
Expression	of	selenomethionine	labeled	AbyA5_QM	employed	the	same	general	method	as	
for	 selenomethionine	 labeled	 wild	 type	 AbyA5,	 however,	 E.	 coli	 B834	 (DE3)	 cells	 pre-
transformed	with	abyA5_QM::	 pOPINF	were	used	 for	 expression,	 and	 growth	media	were	
supplemented	with	carbenicillin	(100	μg/mL)	not	kanamycin.	
All	 recombinant	proteins	were	purified	using	the	same	general	strategy.	Frozen	cell	pellets	
were	thawed	on	ice	and	resuspended	in	30	mL	of	His-Load	buffer	(20	mM	Tris-HCl,	500	mM	
NaCl,	20	mM	imidazole,	2	mM	TCEP,	20%	v/v	glycerol,	pH	7.5)	supplemented	with	an	EDTA	
free	protease	cocktail	tablet	(Sigma	Aldrich).	Cell	suspensions	were	sonicated,	and	resulting	
cell	 lysates	 clarified	 by	 centrifugation.	 Supernatants	were	 removed	 and	 applied	 to	 a	 5	mL	
HisTrap	column	(GE	Life	Sciences)	pre-charged	with	nickel.	Each	column	was	washed	with	10	
column	volumes	of	His-Load	buffer	in	order	to	remove	any	non-specifically	bound	proteins.	
Bound	protein	was	eluted	over	50	mL	using	a	linear	gradient	of	0-50%	His-Load	to	His-Elute	
buffer	(20	mM	Tris-HCl,	500	mM	NaCl,	500	mM	imidazole,	2	mM	TCEP,	20%	glycerol,	pH	7.5),	
with	fractionation	(2	mL)	throughout.	Fractions	found	to	contain	the	target	protein	of	interest,	
as	 determined	 SDS-PAGE	 analysis,	 were	 pooled	 and	 concentrated	 to	 2	mL.	 Proteins	were	
further	purified	by	passage	through	a	a	Hi-Load	16/60	Superdex	200	column	pre-equilibrated	
in	either	20	mM	Tris-HCl,	500	mM	NaCl,	10%	glycerol	pH	8	(unlabeled	wild	type	AbyA5)	or	20	
mM	Tris-HCl,	500	mM	NaCl,	2	mM	TCEP,	10%	glycerol,	pH	8	(selenomethionine	labeled	AbyA5	
and	AbyA5_QM).	Eluted	fractions	found	to	contain	the	target	protein	of	interest	were	pooled,	
concentrated	to	10	mg/mL	and	flash	frozen	in	liquid	nitrogen	for	storage	at	-80	oC.	All	proteins	
were	judged	to	be	>	95%	purity	as	determined	by	SDS-PAGE	analysis	(Fig.	S3).	
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1.3. Protein	crystallization	and	diffraction	data	collection	
Crystallization	screening	was	performed	with	commercially	available	screens	from	Molecular	
Dimensions	Ltd.,	using	the	sitting-drop	vapor-diffusion	method.	Crystallization	experiments	
were	established	using	a	Phoenix	nanolitre	pipetting	robot	(Art	Robbins),	using	96	well	MRC	
plates	 containing	 50	 μL	 of	 each	 crystallization	 condition.	 0.5	 μL	 of	 protein	 solution	 was	
pipetted	into	the	sample	well	followed	by	0.5	μL	of	reservoir	solution.	Plates	were	sealed	with	
clear	sealing	film	and	allowed	to	equilibrate	at	18	°C.	Wild	type	AbyA5	crystals	formed	in	12.5	
%	w/v	PEG	1000,	12.5%	w/v	PEG	3350,	12.5%	v/v	MPD,	0.02	M	sodium	L-glutamate,	0.02	M	
DL-alanine,	0.02	M	glycine,	0.02	M	DL-lysine,	HCl,	0.02	M	DL-serine,	0.1	M	Bicine/Trizma	base	
pH	8.5.	SeMet	labeled	wild	type	AbyA5	crystals	formed	in	12.5%	w/v	PEG	1000,	12.5%	w/v	
PEG	3350,	12.5%	v/v,	0.03	M	sodium	nitrate,	0.03	M	disodium	hydrogen	phosphate,	0.3	M	
ammonium	sulfate	0.1	M	MES/imidazole	pH	6.5.	AbyA5_QM	SeMet	labeled	crystals	formed	
in	0.02	M	magnesium	chloride,	0.1	M	HEPES,	22%	w/v	polyacrylic	acid	5100	sodium	salt,	pH	
7.5.	 Crystals	 selected	 for	 diffraction	 data	 collection	 were	 mounted	 in	 appropriately	 sized	
litholoops	(Molecular	Dimensions	Ltd.),	submerged	in	reservoir	solution	supplement	with	20	
%	glycerol,	and	flash-cooled	in	liquid	nitrogen	prior	to	analysis.	Diffraction	data	were	collected	
at	Diamond	Light	Source,	UK,	using	beamlines	I04	or	I24.	For	each	data	set	1800	images	were	
collected	with	an	oscillation	of	0.2°.	Exposure	time	per	image	was	0.05	s	with	a	beam	flux	of	
100%.	Crystals	were	maintained	at	cryogenic	temperatures	throughout	data	collection.	
	
1.4. Structure	determination	and	refinement	
Diffraction	data	were	processed	with	iMosflm2	and	scaled	and	merged	using	Aimless,3	within	
the	CCP4	software	package.4	5%	of	the	data	were	used	as	a	test	set	for	the	calculation	of	Rfree.	
Identification	of	heavy	atom	sites	and	the	resulting	initial	phase	calculation	were	carried	out	
with	the	Autosol	pipeline	in	the	Phenix	software	package.5	Insufficient	anomalous	signal	was	
observed	in	diffraction	data	collected	from	crystals	of	SeMet	labeled	wild	type	AbyA5,	hence	
the	requirement	to	generate	the	quadruple	methionine	mutant	AbyA5_QM.	The	initial	model	
of	 AbyA5_QM,	 built	 using	 the	 Autobuild	 pipeline	 in	 Phenix,	 was	 further	 extended	 using	
ARP/wARP6	in	the	CCP4	package.	Iterative	rounds	of	manual	model	building	and	refinement	
were	carried	out	using	COOT7	and	REFMAC.8	The	structure	of	wild	type	AbyA5	was	solved	by	
molecular	 replacement	 using	 the	 structure	 of	 the	 AbyA5_QM	mutant	 as	 a	 search	 model	
employing	diffraction	data	collected	from	crystals	of	unlabeled	wild	type	AbyA5.	Data	were	
processed	as	outlined	for	AbyA5_QM.	Molecular	replacement	was	performed	using	Phaser9	
in	 the	CCP4	software	package.	Subsequent	 rounds	of	model	building	and	refinement	were	
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performed	using	COOT	and	REFMAC,	to	yield	the	final	model.	The	Cα	RMSD	between	wild	type	
AbyA5	and	AbyA5_QM	is	0.5	Å,	indicating	that	the	four	methionine	substitutions	introduced	
in	AbyU_QM	do	not	perturb	the	overall	fold	of	the	enzyme.	Structure	validation	and	model	
quality	 assessment	 was	 performed	 using	 PDB	 tools.	 Final	 data	 collection	 and	 refinement	
statistics	for	wild	type	AbyA5	and	AbyA5_QM	are	provided	in	Supplementary	table	1.	Protein	
structure	figures	have	been	prepared	using	PYMOL.10	The	structures	of	wild	type	AbyA5	and	
AbyA5_QM	and	have	been	deposited	in	the	PDB	with	codes	5NO5	and	4YWF,	respectively.	
	
1.5. Acetate	elimination	activity	assays	
The	 ability	 of	 AbyA5	 to	 accept	 the	 compounds	 (R)-9	 and	 (S)-9	 as	 substrates	 for	 acetate	
elimination	was	assessed	in	40	µL	assay	mixes	comprising	25.9	µM	AbyA5,	50	µM	(R)-9	or	(S)-
9,	20	mM	Tris-HCl,	150	mM	NaCl,	5%	acetonitrile,	pH	7.5.	Assays	were	initiated	by	the	addition	
of	cold	enzyme	(4	°C)	and	incubated	for	30	mins	at	25	°C,	following	which	they	were	quenched	
by	 the	 addition	 of	 40	 µL	 of	 ice-cold	 acetonitrile	 and	 centrifuged	 at	 14000	 rpm	 to	 remove	
precipitated	protein.	Control	experiments	were	performed	using	the	assay	mixes	and	reaction	
conditions	described	above,	but	either	excluding	enzyme,	or	using	heat	denatured	enzyme.	
For	 assays	 incorporating	 heat	 denatured	 enzyme	 a	 38	 µL	 27.3	 µM	 solution	 of	 AbyA5	was	
heated	at	100	°C	for	10	mins,	 following	which	2	µL	of	1	mM	substrates	(S)-9	or	(R)-9	were	
added.	Assay	components	were	extracted	to	1	mL	of	ethyl	acetate	and	concentrated	in	vacuo.	
Resulting	residues	were	re-dissolved	in	40	µL	of	acetonitrile,	of	which	20	µL	was	subjected	to	
LC-MS	 analysis.	 Chromatographic	 separations	were	 performed	 using	 a	 Phenomenex	 LUNA	
column	(5	µ,	C18,	100	Å,	4.6	×	250	mm),	using	a	linear	gradient	of	10-95%	acetonitrile/0.5%	
formic	acid.	Mass	spectrometry	was	performed	using	a	Waters	QM	Micromass	spectrometer.	
	
1.6. Acetate	elimination	steady-state	kinetic	studies	
Reaction	rates	for	the	AbyA5	(WT,	and	mutants	H312A	and	Ser198)	catalyzed	conversion	of	
(R)-9	to	10	were	determined	spectrophotometrically	by	monitoring	the	rate	of	appearance	of	
10	at	265	nm	(ε265	nm	=	14400	M-1cm-1).	Reactions	were	performed	in	a	1	mm	path	length	quartz	
cuvette,	 using	 a	 5	 mM	 stock	 solution	 of	 (R)-9	 dissolved	 in	 acetonitrile.	 Reactions	 were	
performed	in	buffer	comprising	20	mM	Tris-HCl,	150	mM	NaCl,	5%	acetonitrile,	pH	7.5,	using	
substrate	concentrations	in	the	range	0-250	µM,	with	AbyA5	at	0.5	µM	final	concentration.	
Initial	rates	were	calculated	by	monitoring	the	change	in	absorbance	for	at	least	2	minutes.	
Background	subtracted	initial	rates	were	plotted	as	a	function	of	substrate	concentration	and	
fitted	to	a	rectangular	hyperbola	of	the	form:		
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!"	 = %&'([*][,]-. + [,] 	
	
Where	v0	is	initial	velocity,	[E]	is	enzyme	concentration,	[A]	is	substrate	concentration	at	time	
0,	kcat	 is	 the	enzyme	catalyzed	reaction	rate	and	Km	 is	 the	Michaelis	constant.	All	 reactions	
were	repeated	in	triplicate.	Data	fitting	was	performed	using	GraphPad	Prism.	
	
1.7. Acetyl	esterase	steady-state	kinetic	studies		
Reaction	 rates	 for	 the	 AbyA5	 catalyzed	 hydrolysis	 of	 p-nitrophenyl	 acetate	 (p-NPA)	 were	
determined	spectrophotometrically	by	monitoring	the	rate	of	disappearance	of	substrate	at	
405	nm	(ε405	nm	=	18,000	M-1cm-1).	Reactions	were	performed	in	a	1	mm	path	length	quartz	
cuvette,	using	a	5	mM	stock	solution	of	p-NPA.	In	order	to	avoid	solubility	issues,	a	50	mM	
stock	solution	of	p-NPA	in	acetonitrile	was	diluted	tenfold	 into	a	buffer	comprising	20	mM	
Tris-HCl,	150	mM	NaCl,	pH	7.5,	to	give	the	5	mM	stock	solution.	Reactions	were	performed	in	
buffer	comprising	20	mM	Tris-HCl,	150	mM	NaCl,	pH	7.5,	using	substrate	concentrations	in	
the	range	0-200	µM,	with	AbyA5	at	0.25	µM	final	concentration.	Substrate	concentrations	>	
200	µM	could	not	be	used	due	to	poor	substrate	solubility	 Initial	 rates	were	calculated	by	
monitoring	the	change	in	absorbance	for	at	least	2	minutes.	Data	analysis	was	performed	as	
for	the	acetate	elimination	assays	outlined	above,	with	all	reactions	repeated	in	triplicate.	
	
1.8.	Docking	studies		
Molecular	 docking	 of	 the	 natural	 substrate	 (R)-3	 and	 its	 enantiomer	 at	 C15	 (S)-3	 was	
performed	using	the	WT	crystal	structure.	The	substrate	and	product	structures	were	initially	
built	with	GaussView	and	then	optimized	at	the	B97D/6-31+G(d,p)	level.	AutoDockTools	1.5.4	
was	 used	 to	 add	 Gasteiger	 charges,	 merge	 the	 non-polar	 hydrogens.	 During	 docking,	 all	
formally	single	rotable	bonds	were	allowed	to	change,	apart	from	the	C3-C4	and	C5-C6	bonds,	
to	 maintain	 an	 all-trans	 conformation	 in	 the	 triene	 chain.	 Subsequently,	 docking	 was	
performed	with	AutoDock	Vina	1.1.2,11	using	a	grid	of	20×28×15	Å	centered	on	the	active	site	
cavity.	The	exhaustiveness	was	set	to	25.	
	
1.9.	Molecular	dynamics	simulations	
Explicit	solvent	molecular	dynamics	simulations	were	performed	of	the	apo-enzyme	and	the	
docked	complexes.	Hydrogens	were	added	with	the	AmberTools12	program	reduce,	with	all	
residues	 in	 their	 standard	 protonation	 states	 (in	 line	with	 predicted	 pKa	 values	 by	 PropKa	
3.1.13,14	 His308,	 His312	 and	 His320	 were	 singly	 protonated	 on	 Nδ1	 and	 other	 His	 singly	
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protonated	on	Nε2	(consistent	with	the	hydrogen	bonding	network	and	the	expected	catalytic	
role	of	His312).	The	missing	N-terminal	residues	1-29	were	omitted	and	Ile30	was	capped	with	
an	acetyl	group.	All	crystallographically	determined	water	molecules	were	kept	for	the	apo	
simulations,	whereas	water	molecules	 in	 the	 active	 site	 cleft	 overlapping	with	 the	docked	
poses	 were	 removed	 for	 the	 simulations	 of	 complexes.	 Subsequently,	 the	 AmberTools	
program	tleap	was	used	to	add	additional	waters	to	form	a	rectangular	box	extending	at	least	
10	Å	from	any	solute	and	crystallographically	determined	water	atom.	5	bulk	water	molecules	
were	replaced	with	sodium	ions	to	neutralize	the	net	charge.	
MD	simulations	were	performed	with	the	Amber14	programs	sander	(for	minimization)	and	
pmemd.cuda	(for	MD	on	GPUs,	using	the	default	SPFP	model)15	and	using	the	AMBER	ff14SB	
force	field	for	the	protein,16	the	TIP3P	water	model	and	GAFF17	for	the	substrates	(parameters	
assigned	with	Antechamber).	Particle-mesh	Ewald	summation	was	used	in	conjunction	with	
periodic	boundary	conditions	and	a	cut-off	for	direct-space	non-bonded	interactions	of	8	Å.	
Partial	 charges	 for	 the	 substrates	 consistent	with	 ff14SB	were	 calculated	 using	 the	 PyRED	
server,18	based	on	three	representative	conformations	of	3-R	from	docking	(identical	charges	
were	 used	 for	 the	 enantiomers).	 Prior	 to	 production	 simulation	 at	 298	 K	 and	 1	 atm,	 the	
following	 procedure	 was	 carried	 out:	 1)	 optimize	 solvent	 and	 hydrogen	 positions	
(minimization	 for	300	steps	with	positional	 restraints	on	non-solvent	heavy	atoms);	2)	300	
steps	of	minimization	and	quick	heating	to	298	K	(20	ps	in	NVT	ensemble	with	2	fs	timestep,	
using	 langevin	 dynamics	 with	 SHAKE	 and	 initial	 random	 velocities	 assigned	 at	 25K)	 with	
harmonic	positional	restraints	on	Cα	atoms	only	(force	constant:	5	kcal	mol−1Å−2);	3)	release	
of	positional	restraints	in	4	steps	of	10	ps	MD	in	the	NPT	ensemble	(langevin	dynamics	with	
PME,	SHAKE	and	timestep	of	2	fs,	a	collision	frequency	of	1	and	the	Berendsen	barostat	with	
a	pressure	relaxation	time	of	1	ps);	4)	1	ns	equilibration	of	temperature	and	pressure	in	the	
NPT	ensemble	(conditions	as	in	previous	step).	Production	simulation	was	then	performed	in	
the	NVT	ensemble	using	weak	temperature	control	(MD	with	SHAKE	and	a	2	fs	timestep,	using	
the	Berendsen	thermostat	with	the	time	constant	for	coupling	to	the	heat	bath	of	10	ps).	Root-
mean-square	 deviation,	 hydrogen	 bond	 and	 distance	 analysis	 was	 performed	 with	 the	
AmberTools	program	cpptraj.	Default	geometrical	parameters	were	used	for	hydrogen	bond	
analysis.	
2.0.	Substrate	synthesis	
All	 reagents	 were	 sourced	 from	 commercial	 suppliers	 and	 were	 used	 without	 further	
purification	unless	stated	otherwise.	Where	anhydrous	conditions	were	necessary,	standard	
Schlenk	 syringe-septa	 techniques	 were	 used	 with	 flame	 dried	 glassware	 under	 a	 positive	
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pressure	of	nitrogen.	Anhydrous	THF,	Et2O,	hexane	and	CH2Cl2	were	dried	by	passing	through	
a	modified	Grubbs	system	of	alumina	columns,	manufactured	by	Anhydrous	Engineering	and	
stored	over	3Å	molecular	sieves.	All	stated	temperatures	below	ambient	are	the	temperatures	
of	the	cooling	baths,	unless	otherwise	stated.	Flash	column	chromatography	was	performed	
according	to	the	procedures	used	by	Still	et	al	using	silica	gel	60	(Fisher	Scientific	or	Aldrich)	
and	a	suitable	eluent.	TLC	was	performed	with	aluminium	backed	silica	TLC	plates	 (Merck-
Kieselgel	60	F254)	with	a	suitable	solvent	system	and	was	visualised	using	UV	fluorescence	(254	
&	366	nm)	and/or	developed	with	potassium	permanganate.	Infra-red	spectra	were	recorded	
on	a	Perkin	Elmer	Spectrum	100	FTIR	with	an	ATR	accessory	and	frequencies	are	reported	in	
wavenumbers	(cm-1).	1H	and	13C	NMR	spectra	were	recorded	using,	Jeol	ECS	400	MHz,	Varian	
400-MR	(400	MHz),	Bruker	Advance	III	HD	500	Cryo	(500	MHz)	and	Varian	VNMR	S600	Cryo	
(600	MHz)	spectrometers	at	ambient	temperature.	Chemical	shifts	(δ)	are	quoted	in	parts	per	
million	(ppm)	and	coupling	constants	(J)	are	in	hertz	(Hz).	Residual	solvent	peaks	were	used	
as	the	internal	reference	for	proton	and	carbon	chemical	shifts.	HRMS	ESI	were	performed	on	
either	a	Bruker	Daltonics	Apex	4,	7	Tesla	FTICR	or	microTOF	 II.	Samples	were	submitted	 in	
MeOH	or	CH2Cl2.	Optical	 rotation	 ([α]TD	 )	was	measured	on	a	Bellingham	and	Stanley	Ltd.	
ADP220	polarimeter	and	is	quoted	in	(°	ml)(g	dm)-1.	
	
(2R)-5,5-Dimethyl-4,6-dioxolane-2-carbaldehyde	SI-1	
	
To	a	stirred	solution	of	1,2:5,6-di-O-isopropylidene-D-mannitol	(2.00	g,	7.62	mmol)	in	CH2Cl2	
(20	mL)	was	added	saturated	sodium	hydrogen	carbonate	solution	(0.80	mL).	The	reaction	
mixture	was	stirred	at	 room	temperature	 for	10	minutes	before	sodium	periodate	 (3.26	g,	
15.25	mmol)	was	added	portion	wise.	The	reaction	was	stirred	for	a	further	3	hours	before	
the	solution	was	filtered	under	gravity	and	concentrated	in	vacuo	to	give	aldehyde	SI-1	(1.97	
g,	 99	%)	 as	 a	 viscous	 colorless	 oil.	 A	 small	 portion	was	 purified	 by	 vacuum	distillation	 for	
characterisation	 purposes.	 The	 remaining	 material	 was	 carried	 through	 without	 further	
purification.	[α]123	=	+38	(c	1.27,	CHCl3)	[Lit.19	+40.0	(c	1.0,	CHCl3)]	.	δH	(400	MHz,	CDCl3)	9.72	
(1H,	d,	J	2.0,	1-H),	4.38	(1H,	ddd,	J	7.5,	4.5,	2.0,	2-H),	4.17	(1H,	dd,	J	9.0,	7.5,	3-HH),	4.10	(1H,	
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dd,	J	9.0,	4.5,	3-HH),	1.49	(3H,	s,	CH3),	1.42	(3H,	s,	CH3);	δC	(100	MHz,	CDCl3)	201.8	(C-1),	111.3	
(C-5),	79.8	(C-2),	65.6	(C-3),	26.2	(CH3),	25.1	(CH3).	All	data	in	accordance	with	the	literature.19	
	
Methyl	(2R)-5,5-dimethyl-4,6-dioxolane-2-carboxylate	SI-2		
	
To	a	stirred	solution	of	aldehyde	SI-1	(4.14	g,	32.02	mmol)	in	a	mixture	of	MeOH	(27	mL)	and	
water	(3	mL)	was	added	solid	sodium	hydrogen	carbonate	(53.8	g,	641	mmol).	The	resultant	
slurry	was	stirred	vigorously	at	room	temperature.	Bromine	(3.26	mL,	64.1	mmol)	was	added	
slowly	over	a	twenty	minutes	period	and	the	reaction	was	stirred	for	a	further	2	hours.	The	
reaction	was	slowly	quenched	with	saturated	aq.	sodium	thiosulfate	solution	 (30	mL)	 then	
passed	through	a	sinter	funnel.	The	resultant	solution	was	extracted	with	CH2Cl2	(3	×	30	mL).	
The	combined	organic	layers	were	dried	(MgSO4),	filtered	under	gravity	and	concentrated	in	
vacuo	to	give	ester	SI-2	(5.08	g,	99	%)	as	a	colorless	liquid.	[α]123	=	+15.3	(c	0.98,	CHCl3)	[Lit.20	
+17.0	(c	1.00,	CHCl3)]	.	δH	(400	MHz,	CDCl3)	4.59	(1H,	dd,	J	7.0,	5.0,	2-H),	4.24	(1H,	dd,	J	8.5,	7.0,	
3-HH),	4.10	(1H,	dd,	J	8.5,	5.0,	3-HH),	3.77	(3H,	s,	OCH3),	1.49	(3H,	s,	CH3),	1.40	(3H,	s,	CH3);	δC	
(100	MHz,	CDCl3)	171.6	(C-1),	111.4	(C-5),	74.0	(C-2),	67.2	(C-3),	52.4	(OCH3),	25.8	(CH3),	25.5	
(CH3).	All	data	in	accordance	with	the	literature.20		
	
Methyl	(2R)-2,3-dihydroxypropanoate	SI-3		
	
To	a	solution	of	ester	SI-2	(1.30	g,	8.12	mmol)	in	MeOH	(10	mL)	was	added	acidified	Dowex®	
50WX8	 resin	 (1.20	g).	 The	 reaction	mixture	was	 stirred	 for	15	hours	at	 room	temperature	
before	the	solution	was	filtered	under	gravity	and	concentrated	in	vacuo	to	give	diol	SI-3	(970	
mg,	98	%)	as	a	colorless	oil.	[α]123	=	+6.0	(c	1.00,	CHCl3)	[Lit.21	+6.6	(c	4.8,	CHCl3)].	δH	(400	MHz,	
CDCl3)	4.28	(1H,	t,	J	3.5,	2-H),	3.91	(1H,	dd,	J	12.0,	3.5,	3-HH),	3.84	(1H,	dd,	J	12.0,	3.5,	3-HH),	
3.83	(3H,	s,	OCH3),	2.60	(2H,	br	s,	OH);	δC	(100	MHz,	CDCl3)	173.6	(C-1),	71.7	(C-2),	64.2	(C-3),	
53.1	(OCH3).	All	data	in	accordance	with	the	literature.21	
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Methyl	(2R)-3-(tert-butyldimethylsilyloxy)-2-hydroxypropanoate	5		
	
Diol	SI-3	(1.40	g,	11.7	mmol)	was	dissolved	in	dry	CH2Cl2	(30	mL)	under	a	nitrogen	atmosphere.	
Imidazole	(2.39	g,	35.1	mmol)	was	added	to	the	solution	and	the	reaction	was	stirred	for	5	
minutes	at	room	temperature.	TBSCl	(1.94	g,	12.9	mmol)	was	then	added	and	the	reaction	
stirred	for	a	further	24	hours.	The	solution	was	then	acidified	with	HCl	(1	M,	15	mL)	and	the	
layers	separated.	The	organic	layer	was	washed	with	saturated	aq.	NaHCO3	(10	mL)	and	brine	
(10	mL)	before	being	dried	 (MgSO4),	 filtered	under	gravity	and	concentrated	 in	vacuo.	The	
residue	was	purified	by	column	chromatography	eluting	with	10	%	EtOAc	in	petroleum	ether	
40-60	°C	to	give	ester	5	(2.74	g,	81	%)	as	a	colorless	oil.	[α]123	=	-8.6	(c	1.2,	CH2Cl2)	[Lit.22	-9.3	
(c	1.5,	CH2Cl2)].	δH	(400	MHz,	CDCl3)	4.22	(1H,	dt,	J	8.0,	3.0,	2-H),	3.92	(1H,	dd,	J	10.0,	3.0,	3-
HH),	3.85	(1H,	dd,	J	10.0,	3.0,	3-HH),	3.77	(3H,	s,	OCH3),	3.04	(1H,	d,	J	8.0,	OH),	0.86	(9H,	s,	
(SiC(CH3)3),	0.05	and	0.03	(each	3H,	each	s,	Si(CH3)2);	δC	(100	MHz,	CDCl3)	173.3	(C-1),	72.1	(C-
2),	65.2	(C-3),	52.5	(OCH3),	25.9	(SiC(CH3)3),	18.4	((SiC(CH3)3),	-5.3	and	-5.5	(Si(CH3)2).	All	data	
in	accordance	with	the	literature.22	
	
	
Methyl	(2S)-3-(tert-butyldimethylsilyloxy)-2-hydroxypropanoate	SI-5		
	
Alcohol	5	(0.50	g,	2.14	mmol)	and	triphenylphosphine	(1.12	g,	4.27	mmol)	were	dissolved	in	
dry	THF	(10	mL)	under	a	nitrogen	atmosphere	and	cooled	to	-78	°C.	Acetic	acid	(0.24	mL,	4.27	
mmol)	and	DIAD	(0.84	mL,	4.27	mmol)	were	added	sequentially	at	-78	°C	and	the	resulting	
bright	yellow	solution	was	allowed	to	warm	to	room	temperature	over	4	hours.	Upon	warming	
the	bright	yellow	solution	became	a	white	precipitate,	by	0	°C	it	became	a	colorless	solution.	
The	 reaction	 was	 concentrated	 under	 reduced	 pressure	 and	 the	 residue	 was	 purified	 by	
column	chromatography	eluting	with	5%	EtOAc	in	petroleum	ether	40-60	°C	to	give	ester	SI-4	
(0.51	g,	87%)	as	a	colorless	oil.	Ester	SI-4	(480	mg,	1.73	mmol)	was	dissolved	in	HPLC	grade	
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MeOH	(10	mL)	and	sodium	methoxide	(5	mg,	0.09	mmol)	was	added.	The	resulting	solution	
was	stirred	at	room	temperature	for	4	hours.	The	reaction	was	quenched	by	the	addition	of	
saturated	aq.	NH4Cl	(15	mL)	followed	by	water	(10	mL)	and	extracted	with	EtOAc	(3	×	15	mL).	
The	 combined	 organic	 phases	 were	 washed	 with	 brine	 (10	 mL),	 dried	 (MgSO4)	 and	
concentrated	in	vacuo.	The	residue	was	purified	by	column	chromatography	eluting	with	5-
7%	EtOAc	in	petroleum	ether	40-60	°C	to	give	alcohol	SI-5	as	a	colorless	oil	(310	mg,	77%).	[α]123 	=	+6.1	 (c	 1.1,	 CHCl3).	 All	 data	 in	 accordance	with	 the	 literature	 and	 (R)	 enantiomer	
above.22	
	
1-(tert-Butylsulfanyl)decane-1,3-dione	6	
	
To	a	stirred	solution	of	Meldrum’s	acid	(500	mg,	3.47	mmol)	and	DMAP	(847	mg,	6.94	mmol)	
in	CH2Cl2	 (10	mL)	at	0	 °C	was	added	octanoyl	chloride	 (0.64	mL,	3.82	mmol).	The	resulting	
bright	yellow	solution	was	stirred	at	0	°C	for	30	minutes	before	warming	to	room	temperature	
for	30	minutes.	The	reaction	was	quenched	by	the	addition	of	1	M	HCl	(10	mL)	and	extracted	
with	CH2Cl2	(3	×	15	mL).	The	combined	organic	phases	were	washed	with	brine	(20	mL),	dried	
(MgSO4)	and	concentrated	in	vacuo	to	give	a	bright	yellow	oil	which	was	redissolved	in	toluene	
(5.25	 mL).	 2-Methyl-2-propanethiol	 (1.17	 mL,	 10.4	 mmol)	 was	 added	 then	 the	 reaction	
mixture	was	heated	to	100	°C	for	1	hour.	The	solution	was	cooled	to	room	temperature	before	
the	 volatiles	 were	 removed	 in	 vacuo.	 The	 resultant	 residue	 was	 purified	 by	 column	
chromatography	eluting	with	2-4%	EtOAc	in	petroleum	ether	40-60	°C	to	yield	thioester	6	(807	
mg,	90	%	over	two	steps)	as	an	orange/pink	oil	 in	a	4:1	mixture	of	keto:enol	tautomers.	δH	
(400	MHz,	CDCl3)	12.87	(1H,	s,	OH)[Enol],	5.32	(1H,	s,	2-H)[Enol],	3.55	(2H,	s,	2-H2)[Keto],	2.52	
(2H,	 t,	 J	 7.5,	4-H2)[Keto],	2.12	 (2H,	 t,	 J	 7.5,	4-H2)[Enol],	1.51	 (9H,	 s,	CH3)[Enol],	1.47	 (9H,	 s,	
CH3)[Keto],	1.23-1.32	(10H,	m),	0.87	(3H,	t,	J	7.0,	CH3);	δc	(100	MHz,	CDCl3)	202.7	(C-3),	192.8	
(C-1),	58.6	(C-2),	49.2	(SC(CH3)3),	43.3	(C-4),	31.8	(CH2),	30.3	(CH2),	29.8	(SC(CH3)3),	29.1	(C-6),	
23.6	(C-5),	22.7	(C-9),	14.2	(9-CH3);	IR	(vmax/cm-1)	(neat):	1615	(thioester	[enol	form]	C=O),	1676	
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(thioester	[keto	form]	C=O),	1724	(ketone	C=O),	2857	(alkane	C-H),	2926	(alkane	C-H);	HRMS	
(ESI)	calc.	for	[C14H26O2S+Na]+	281.1546.	Found	281.1535.	
	
(2R)-3-(tert-Butyldimethylsilyloxy)-1-methoxy-1-oxopropan-2-yl	3’-oxodecanoate	7	
	
Alcohol	5	(287	mg,	1.23	mmol)	and	thioester	6	(380	mg,	1.47	mmol)	were	dissolved	in	THF	(13	
mL)	before	adding	4	Å	molecular	sieves	and	cooling	to	0	°C.	Silver	trifluoroacetate	(407	mg,	
1.84	mmol)	was	added	in	a	single	portion,	shielded	from	light	and	stirred	for	2	hours.	Upon	
completion	the	reaction	mixture	was	filtered	through	a	short	pad	of	celite,	washed	with	Et2O,	
concentrated	in	vacuo.	Column	chromatography	eluting	with	3-5%	EtOAc	in	petroleum	ether	
40-60	°C	gave	desired	ester	7	as	a	colorless	oil	(332	mg,	67%)	in	a	4:1	mixture	of	keto	and	enol	
tautomers.	δH	(400	MHz,	CDCl3)	11.75	(1H,	s,	OH)[Enol],	5.18	(1H,	dd,	J	5.0,	3.0,	2-H)[Keto],	
4.04	(1H,	dd,	J	11.5,	5.00,	3-HH)[Keto],	3.96	(1H,	overlapping	dd,	3-HH)[Enol],	3.94	(1H,	dd,	J	
11.5,	3.00,	3-HH)[Keto],	3.86	(1H,	dd,	J	11.5,	3.00,	3-HH)[Enol],	3.78	(3H,	s,	OCH3)[Enol],	3.76	
(3H,	s,	OCH3)[Keto],	3.53	(2H,	s,	2’-H2)[Keto],	2.59	(2H,	t,	J	7.5,	4’-H2)[Keto],	2.21	(2H,	t,	J	7.5,	
4’-H2)[Enol],	1.62-1.55	(2H,	m,	5’-H2)[Keto	and	enol],	1.34-1.20	(8H,	m,	6’,	7’,	8’	and	9’-H2)[Keto	
and	enol],	0.90-0.87	(3H,	m,	10’-H3)[Keto	and	enol],	0.87	(9H,	s,	SiC(CH3)3)[Keto	and	enol],	0.05	
(6H,	 s,	 Si(CH3)2)[Keto	 and	 enol].	 δc	 (100	MHz,	 CDCl3)	 202.4	 (C-3’)[Keto],	 168.3	 (C-1)[Keto],	
166.8	(C-1’)[Keto],	74.4	(C-2)[Keto],	72.1	(C-2)[Enol],	65.2	(C-3)[Enol],	62.7	(C-3)[Keto],	52.5	
(OCH3)[Keto],	 49.1	 (C-2’)[Keto],	 43.1	 (C-4’)[Keto],	 31.8	 (CH2)[Keto],	 29.2	 (CH2)[Keto],	 29.1	
(CH2)[Keto],	25.8	(SiC(CH3)3)[Keto],	23.6	(C-5’)[Keto],	22.7	(CH2)[Keto],	18.3	(SiC(CH3)3)[Keto],	
14.2	(C-10’)[Keto],	-	5.3	(Si(CH3)2)[Keto]	and	-5.4	(Si(CH3)2)[Keto].	IR	(vmax/cm-1)	(neat):	1719	
(ketone	 C=O),	 1749	 (ester	 C=O),	 2857,	 2828	 and	 2960	 (alkane	 C-H)	 HRMS	 (ESI)	 calc.	 for	
C20H38NaO6	425.2330.	Found	425.2327.;		
	
(5R)-4-Hydroxy-5-(hydroxymethyl)-3-octanoylfuran-2(5H)-one	8	
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Ester	7	(140	mg,	0.35	mmol)	was	dissolved	in	THF	(4	mL)	and	cooled	to	0	°C.	TBAF	(1.0	M	in	
THF,	0.52	mL,	0.52	mmol)	was	added	dropwise	and	the	solution	was	stirred	at	0	°C	for	1	hour	
then	warmed	to	room	temperature	for	a	further	2	hours.	TBAF	(1.0	M	in	THF,	0.23	mL,	0.23	
mmol)	was	added	dropwise	and	the	solution	stirred	overnight.	The	reaction	was	quenched	by	
the	 addition	 of	 saturated	 aq.	 NH4Cl	 (10	 mL)	 and	 extracted	 with	 EtOAc	 (3	 ×	 15	 mL).	 The	
combined	organic	phases	were	washed	with	brine	(15	mL),	dried	(MgSO4)	and	concentrated	
in	 vacuo.	 The	 crude	 oil	 was	 purified	 by	 column	 chromatography	 eluting	 with	 0:100	
MeOH:EtOAc	to	6:94	MeOH:EtOAc	to	give	tetronate	8	as	a	white	solid	(63	mg,	71%).	δH	(400	
MHz,	MeOD)	4.77	(1H,	t,	J	3.0,	5-H),	3.92	(1H,	dd,	J	12.5,	3.0,	6-HH),	3.87	(1H,	dd,	J	12.5,	3.0,	
6-HH),	2.85	(2H,	t,	J	7.5,	4’-H2),	1.64	(2H,	p,	J	7.5,	5’-H2),	1.39-1.21	(8H,	m,	6’,	7’,	8’	and	9’-H2),	
0.86	(3H,	t,	J	7.0,	10’-H3);	δc	(100	MHz,	MeOD)	195.9	(C-4),	195.4	(C-3’),	173.1	(C-2),	101.6	(C-
3),	83.8	(C-5),	61.0	(C-6),	36.1	(C-4’),	32.8	(CH2),	30.3	(CH2),	30.0	(CH2),	26.4	(C-5’),	23.6	(CH2),	
14.4	 (C-10’).	HRMS	 (ESI)	 calc	 for	C13H19O5	 [M-H]-	 255.1238	 found	255.1227.	 IR	 (vmax/cm-1)	
(neat):	 1663	 (ketone	 C=O),	 1746	 (ester	 C=O),	 2849	 (alkane	 C-H),	 2917	 (alkane	 C-H),	 2954	
(alkane	C-H)	3232	and	3332	(vinylogous	acid	(O-H).	
	
(5R)-4-Hydroxy-5-(acetoxymethyl)-3-octanoylfuran-2(5H)-one	(R)-9	
	
Tetronate	8	(45	mg,	0.18	mmol)	and	DMAP	(3	mg,	cat.)	were	dissolved	in	anhydrous	CH2Cl2	(4	
mL)	and	cooled	to	0	°C.	NEt3	(0.07	mL,	0.53	mmol)	then	acetic	anhydride	(0.03	mL,	0.35	mmol)	
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were	added	dropwise	to	the	solution	was	stirred	at	0	°C	for	1	hour	before	the	reaction	was	
quenched	by	the	addition	of	saturated	aq.	NH4Cl	(6	mL)	and	extracted	with	CH2Cl2	(3	×	20	mL).	
The	 combined	 organic	 phases	 were	 washed	 with	 brine	 (20	 mL),	 dried	 (MgSO4)	 and	
concentrated	 in	 vacuo.	 The	 residue	 was	 purified	 by	 column	 chromatography	 eluting	 with	
100%	 EtOAc.	 Product	 rich	 fractions	 were	 washed	 with	 1	 M	 HCl	 (2	 ×	 15	 mL),	 dried	 and	
concentrated	 to	 give	 tetronate	 (R)-9	 as	 a	 cream	 solid	 (40	mg,	 76	%).	[α]123 	+43.0	 (c	 1.2	 in	
CHCl3);	δH	(400	MHz,	MeOD)	4.94	(1H,	m,	5-H),	4.49	(1H,	dd,	J	12.5,	3.0,	6-HH),	4.30	(1H,	dd,	J	
12.5,	4.0,	6-HH),	2.86	(2H,	t,	J	7.5,	4’-H2),	1.95	(3H,	s,	CH3CO2),	1.63	(2H,	p,	J	7.5,	5’-H2),	1.35-
1.22	(8H,	m,	6’,	7’,	8’	and	9’-H2)	and	0.84	(3H,	t,	J	7.0,	10’-H3);	δc	(100	MHz,	MeOD)	195.3	(C-
4),	194.5	(C-3’),	172.7	(C-2),	171.7	(CH3CO2),	100.5	(C-3),	80.7	(C-5),	62.9	(C-6),	35.8	(C-4’),	32.8	
(CH2),	30.2	(CH2),	30.0	(CH2),	26.7	(C-5’),	23.6	(CH2),	20.4	(CH3CO2),	14.4	(C-10’).	HRMS	(ESI)	
calc	for	C15H22NaO6	[M+Na]+	321.1309	found	321.1311.	(vmax/cm-1)	(neat):	1663	(ketone	C=O),	
1738	(ester	C=O),	1738	(ester	C=O),	2849	(alkane	C-H),	2917	(alkane	C-H),	2955	(alkane	C-H).		
	
(2S)-3-(tert-Butyldimethylsilyloxy)-1-methoxy-1-oxopropan-2-yl	3’-oxodecanoate	SI-6	
	
Alcohol	SI-5	(145	mg,	0.62	mmol)	and	thioester	6	(239	mg,	0.93	mmol)	were	dissolved	in	THF	
(6	mL)	before	adding	4	Å	molecular	sieves	and	cooling	to	0	°C.	Silver	trifluoroacetate	(205	mg,	
0.93	mmol)	was	added	in	a	single	portion,	shielded	from	light	and	stirred	for	2	hours.	Upon	
completion	the	reaction	mixture	was	filtered	through	a	short	pad	of	celite	and	silica,	washed	
with	Et2O	(20	mL),	concentrated	in	vacuo.	Column	chromatography	eluting	with	3-5%	EtOAc	
in	petroleum	ether	40-60	°C	gave	desired	ester	SI-6	as	a	colorless	oil	(199	mg,	79%)	in	a	4:1	
mixture	of	keto	and	enol	tautomers	in	CDCl3.	All	data	in	accordance	with	enantiomer.	
	
(5S)-4-Hydroxy-5-(hydroxymethyl)-3-octanoylfuran-2(5H)-one	SI-7	
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Ester	SI-6	(178	mg,	0.44	mmol)	was	dissolved	in	THF	(5	mL)	and	cooled	to	0	°C.	TBAF	(1.0	M	in	
THF,	0.66	mL,	0.66	mmol)	was	added	dropwise	and	the	solution	was	stirred	at	0	°C	for	1	hour	
before	warming	to	room	temperature	for	2	hours.	TBAF	(1.0	M	in	THF,	0.44	mL,	0.44	mmol)	
was	added	dropwise	and	the	solution	stirred	overnight.	The	reaction	was	quenched	by	the	
addition	1	M	HCl	 (10	mL)	and	extracted	with	EtOAc	(3	×	15	mL).	Combined	organic	phases	
were	washed	with	brine	(15	mL),	dried	(MgSO4)	and	concentrated	in	vacuo.	The	crude	oil	was	
purified	by	column	chromatography	eluting	with	0:100	MeOH:EtOAc	to	10:90	MeOH:EtOAc	
to	 give	 tetronate	 SI-7	 as	 an	 off	 white	 solid	 (103	 mg,	 88%).	 All	 data	 in	 accordance	 with	
enantiomer.	
	
(5S)-4-Hydroxy-5-(acetoxymethyl)-3-octanoylfuran-2(5H)-one	(S)-9	
	
Tetronate	SI-7	(67	mg,	0.26	mmol)	and	DMAP	(3	mg,	cat.)	were	dissolved	in	anhydrous	CH2Cl2	
(6	mL)	and	cooled	to	0	°C.	NEt3	(0.11	mL,	0.785	mmol)	followed	by	acetic	anhydride	(0.05	mL,	
0.52	mmol)	were	added	dropwise	to	the	solution	stirred	at	0	°C	for	1	hour	before	the	reaction	
was	quenched	by	the	addition	of	saturated	aq.	NH4Cl	(10	mL)	and	extracted	with	CH2Cl2	(3	×	
30	mL).	The	combined	organic	phases	were	washed	with	brine	(10	mL),	dried	(MgSO4)	and	
concentrated	 in	 vacuo.	 The	 residue	was	purified	by	 silica	gel	 chromatography	eluting	with	
100%	EtOAc	to	5%	MeOH	in	EtOAc.	Product	rich	fractions	were	washed	with	1	M	HCl	(2	×	15	
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mL),	dried	and	concentrated	to	give	tetronate	(S)-9	as	a	white	solid	(63	mg,	81%).	[α]123	-46.3	
(c	1.1	in	CHCl3).	All	data	in	accordance	with	enantiomer.	
	
3-(1-Hydroxyoctyl)-4-methoxy-5-methylenefuran-2(5H)-one	12	
	
Diisopropylamine	(0.27	mL,	1.92	mmol)	was	dissolved	in	anhydrous	THF	(14.7	mL)	and	cooled	
to	 0	 °C	 under	 an	 atmosphere	of	 nitrogen.	n-BuLi	 (1.6	M,	 1.20	mL,	 1.92	mmol)	was	 added	
dropwise,	and	then	the	mixture	was	stirred	at	0	°C	for	30	minutes	followed	by	cooling	to	-100	
°C.	Tetronate	11	(210	mg,	1.60	mmol)	in	anhydrous	THF	(7	mL)	was	added	dropwise,	and	then	
the	reaction	was	stirred	at	-100	°C	for	10	min.	Octanal	(0.50	mL,	3.20	mmol)	in	anhydrous	THF	
(9	mL)	was	added	dropwise,	and	then	the	reaction	was	further	stirred	at	-100	°C	for	1	hour.	
Saturated	aq.	NH4Cl	(20	mL)	was	added,	and	the	aqueous	phase	was	extracted	with	EtOAc	(3	
×	 50	mL).	 The	 combined	 organic	 layers	 were	 dried	 (MgSO4),	 filtered	 and	 concentrated	 in	
vacuo.	 The	 crude	product	was	 purified	 by	 flash	 column	 chromatography	 eluting	with	 15%	
EtOAc	in	petroleum	ether	40-60	°C	giving	alcohol	12	(370	mg,	92%)	as	a	colorless	oil.	δH(500	
MHz,	CDCl3)	5.07	(1H,	d,	J	2.7,	6’-HH),	5.06	(1H,	d,	J	2.7,	6’-HH),	4.80	(1H,	br	t,	J	6.2,	1-H),	4.13	
(3H,	s,	4’-OCH3),	3.03	(1H,	br	s,	1-OH),	1.91	(1H,	m,	2-HH),	1.46	(1H,	m,	3-HH),	1.75	(1H,	m,	2-
HH),	1.20-1.37	(9H,	m,	2-H2,	3-HH,	4-H2,	5-H2,	6-H2),		0.87	(3H,	t,	J	6.9,	8-H3);	δC(125	MHz,	CDCl3)	
169.7	(C-4’),	160.9	(C-2’),	149.5	(C-5’),	107.4	(C-3’),	93.4	(C-6’),	66.4	(C-1),	60.4	(4’-OCH3),	37.9	
(C-2),	26.2	(C-3),	31.2	(C-4,	C-5,	C-6,	C-7),	29.5,	29.3,	22.8,	14.2	(C-8);	Found	(ESI):	277.1417	
[M+Na]+,	(required	C14H22O4Na	277.1410);	νmax/cm-1	3455,	2955,	2925,	2856,	1756,	1619.	
	
4-Methoxy-5-methylene-3-octanoylfuran-2(5H)-one	13	
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Alcohol	 12	 (150	 mg,	 0.59	 mmol)	 was	 dissolved	 in	 anhydrous	 CH2Cl2	 (3.4	 mL)	 under	 an	
atmosphere	of	nitrogen.	Dess-Martin	periodinane	 (15	wt%,	1.54	mL)	was	added	dropwise,	
and	then	the	reaction	was	stirred	at	room	temperature	for	2	hours.	Saturated	aq.	NaHCO3	(5	
mL)	was	added,	and	the	aqueous	phase	was	extracted	with	EtOAc	(3	×	20	mL).	The	combined	
organic	phases	were	dried	(MgSO4),	 filtered	and	concentrated	 in	vacuo.	The	crude	product	
was	purified	by	flash	column	chromatography	eluting	10%	EtOAc	in	petroleum	ether	40-60	°C	
giving	ketone	13	(210	mg,	69%)	as	a	colorless	oil.	δH(400	MHz,	CDCl3)	5.27	(1H,	d,	J	2.8,	6’-HH),	
5.21	(1H,	d,	J	2.8,	6’-HH),	4.15	(3H,	s,	4’-OCH3),	2.96	(2H,	t,	J	7.5,	2-H2),	1.57-1.67	(2H,	m,	7-H2),	
1.21-1.38	(8H,	m,	3-H2,	4-H2,	5-H2,	6-H2),	0.87	(3H,	t,	J	6.7,	8-H3);	δC(100	MHz,	CDCl3)	197.4	(C-
1),	168.0	(C-4’),	166.6	(C-2’),	149.1	(C-5’),	105.5	(C-3’),	95.9	(C-6’),	63.3	(4’-OCH3),	43.0	(C-2),	
24.1	(C-3),	31.8,	29.3,	29.2	and	22.8	(C-4,	C-5,	C-6	and	C-7),	14.2	(C-8);	Found	(ESI):	275.1262	
[M+Na]+,	(required	C14H20O4Na	275.1254);	νmax/cm-1	2954,	2926,	2856,	1768,	1686.	
	
4-Hydroxy-5-methylene-3-octanoylfuran-2(5H)-one	10	
	
Tetronate	13	 (130	mg,	0.52	mmol)	was	dissolved	 in	DMSO	 (19	mL)	and	LiCl	 (290	mg,	6.73	
mmol)	was	added.	The	mixture	was	heated	to	50	°C	and	stirred	at	the	same	temperature	for	
16	hours.	HCl(aq)	(2	M,	10	mL)	and	EtOAc	(40	mL)	were	added,	and	then	the	aqueous	phase	
was	 extracted	with	 EtOAc	 (3	 ×	 40	mL).	 The	 combined	 organic	 layers	were	 dried	 (MgSO4),	
filtered	 and	 concentrated	 in	 vacuo.	 The	 crude	 product	 was	 purified	 by	 flash	 column	
chromatography	eluting	with	0-2%	MeOH	in	EtOAc	followed	by	washing	with	HCl(aq)	(2	M,	5	
	 18	
mL)	giving	tetronic	acid	10	(80	mg,	64%)	as	a	yellow	cream	solid.	δH(400	MHz,	CDCl3)	9.91	(1H,	
br	s,	OH),	5.45	(1H,	d,	J	2.8,	6’-HH),	5.33	(1H,	d,	J	2.8,	6’-HH),	2.90	(2H,	t,	J	7.4,	2-H2),	1.69	(2H,	
p,	J	7.4,	3-H2),	1.22-1.43	(8H,	m,	4-H2,	5-H2,	6-H2,	7-H2),	0.87	(3H,	t,	J	6.8,	8-H3);	δC(100	MHz,	
CDCl3)	200.4	(C-1),	180.6	(C-4’),	164.2	(C-2’),	148.4	(C-5’),	101.0	(C-3’),	97.7	(C-6’),	37.9	(C-2),	
31.7	(C-3),	29.2,	29.1	and	24.4(C-4,	C-5,	C-6	and	C-7),	22.7,	14.2	(C-8);	Found	(ESI):	239.1287	
[M+H]+,	(required	C13H19O4	239.1278);	Found	(ESI):	261.1104	[M+Na]+,	(required	C13H18O4Na	
261.1097);	νmax/cm-1	3197,	2958,	2924,	2855,	1770,	1651,	1593.		
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2.	Supplementary	Tables	
	
Table	S1.	Summary	of	X-ray	data	collection	and	refinement	statistics	
	
	 AbyA5_QM	SeMet	 AbyA5_WT		
Data	collection	 	 	
Space	group	 C121	 P121	
Cell	dimensions	 	 	
				a,	b,	c	(Å)	 92.1,	87.2,	47.9	 69.2,	88.4,	131.3	
					α,	β,	γ	(°)	 90,	101.6,	90	 90,	90,	90	
Wavelength	(Å)	 0.9769	 0.97888	
Resolution	(Å)	 62.68	-	2.30	(2.38	-	
2.30)	
	
	
41.93	-	2.50	(2.60	-	
2.50)	
	Rmerge	(%)	 0.065	(0.290)	 0.348	(1.332)	
I/σI	 19.3	(7.9)	 6.8	(3.1)	
CC1/2	(%)	 0.998	(0.994)	 0.981	(0.958)	
Completeness	(%)	 100	(100)	 96.7	(96.7)	
Redundancy	 11.0	(10.5)	 11.8	(11.8)	
No.	Se	sites	 15	 -	
FOM	 0.434	 -	
Refinement	 	 	
Resolution	(Å)	 62.68	-	2.30	 41.93	-	2.50		
No.	reflections	 182,519	(16,863)	 325,296	(35,797)	
Rwork/Rfree	 0.23/0.24	 0.19/0.26	
No.	atoms	 2543	 5377	
				Protein	 2493	 5269	
				Ligand	 -	 -	
				Water	 50	 108	
B-factors	Å2	 	 	
				Protein	 32.01	 16.06	
				Ligand	 -	 -	
				Water	 30.50	 9.46	
r.m.s.	deviations	 	 	
				Bond	lengths	(Å)	 0.0159	 0.0130	
				Bond	angles	(°)	 1.7620	 1.6669	
	
Values	in	parentheses	are	for	highest-resolution	shell. 
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Table	S2.	Comparative	kinetic	parameters	of	AbyA5	and	selected	acetylesterases	for	p-
NPA.	
	
	
Enzyme	
	
kcat		
(min-1)	
Km	
(mM)	
kcat/Km	
(min-1mM-1)	
Reference	
AxeA	 4200	 0.12	±	0.08	 35000	 23	
CAH	 4710	±	200	 0.29	±	0.01	 16000	 24		
Ape1a	 522	±	24	
	
0.6	±	0.1	 870	 25		
AbyA5	 44	±	2	
	
0.08	±	0.01	 560	 This	study	
Axe2	 1860	 27	 69	 26		
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3.	Supplementary	Figures	
	
	
	
	
	
	
	
Fig.	S1.	Proposed	abyssomicin	C	biosynthetic	pathway.	The	multienzyme	polyketide	synthase	
AbyB1-3	biosynthesizes	an	acyl-CoA	derived	linear	precursor,	which	is	subsequently	fused	to	
a	C3-unit	tethered	to	the	acyl	carrier	protein	AbyA3.	The	resulting	tetronate	ring	is	acetylated	
at	C15	by	AbyA4,	followed	by	the	AbyA5	catalyzed	acetate	elimination	to	give	an	exocyclic	
methylene	at	this	position.	A	[4	+	2]	cycloaddition	reaction,	catalyzed	by	the	Diels-Alderase	
AbyU,	generates	 the	heterobicyclic	core	of	abyssomicin	C,	which	 is	 subjected	to	additional	
enzyme	catalyzed	tailoring	modifications	to	yield	the	natural	product.	
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Fig.	S2.	Amino	acid	sequence	alignment	of	AbyA5	with	known	and	putative	acetate	lyases.	
Comparative	sequence	alignment	of	AbyA5	with	known	acetate	 lyases.	 Included	are	ChlD4	
(chlorothricin),	 QmnD4	 (quartromicin),	 Agg5	 (agglomerin	 A),	 LobE	 (Lobophorin,	 C-terminal	
domain),	 KijE	 (kijanimicin,	 C-terminal	 domain),	 and	 Tmn17	 (tetronomycin).	 Amino	 acids	
conserved	in	all	acetate	lyases	included	in	this	analysis	are	highlighted	in	red.	The	locations	of	
the	residues	L66,	L158,	L195	and	L295	are	indicated	with	asterisks.	Sequence	alignments	were	
performed	 using	 Clustal	 Omega.27,28	 The	 figure	 was	 generated	 using	 BOXSHADE	
(http://www.ch.embnet.org/software/BOX_form.html).		
AbyA5    1 MSNDVAELKQYVLAHVSAQNAS---ADGVLARIDDD-GDGPRSWTTQWIRAGEEREQAGD
ChlD4    1 -MHDVVELKRYVEVHARGQRIQG--YRDILGRIGSDEGDGPGTWVAEWSRAGEDLAREGR
QmnD4    1 -MNDVEELKQFALVHARTQGIPPGLTDAVLARITTDDAGNPGSWTGEWSREAEAHEARHQ
Agg5     1 --MMLDELKNFVLLHSNVLNVGAE-TRAILPDIHHLGDDLPHSWSQMFYRQAQHYENQGE
LobE     1 --NDVGELKQFVLAHTKGQGIAR--HEEVLARIRTD-TEGDGSWTAEWSRSARELERRGR
KijE     1 --NDVGELKRFVLAHTRGQNVPH--HEEVLARVRTD-ADGDGSWTAEWSRSARALERHGR
Tmn17    1 -MNDVTELKEFARVHAKALQLPAERYDEVLAGITSDEDGAPGSWTAQWSAMAGELEDAGE
AbyA5   57 LLAATTFYNLARFPFVDSPGRAEALRRCVAVFDRWRRTV-PGIERLELRLPGGVVRAWAA
ChlD4   58 PLEASRHFAMARFPYVDGPGRHRALERCAQTLEEWQRERAPELERLDVVLPGGRVRCWST
QmnD4   60 LVEASRLYTMARFPFVDGPARQQALDKVVQTFARS----GSGLEPFQVDTPAGVVRCWRG
Agg5    58 LLKACSLYNLARFPYPETPLQHECNRHCQRLFRRQYIES-GTV--TRVSLSQGRQVCYVR
LobE    56 LLDSCRHHAMARFPFVDGPARRRAQDETVRTFDEWRRAD-KDIERLEVDLPAGRVVAWAT
KijE    56 LLDACRHHSMARFPFVDGPARRRALEETVRTFDQWRRAD-GDIERLEVDLPAGRVAAWAT
Tmn17   60 LLPAFLCYTLARFPVVDGPARQAAYQKCRSVFDRWRAGQ-PDIQRVTASPAGREVVAWAG
AbyA5  116 GLSTTERRPVLLMTGGIVSIKEQWAPILPELARYGFAAVVTELPGVGENELRYDLDSAAL
ChlD4  118 GLSTTRRLPLVLIMGGIVTVKEQWVPALVRLRRLGLAAVVTEMPGVGENTLPYDAKSWRM
QmnD4  116 GT-----GPLVLVSGGIVSIKEQWAGLLGQLIGAGLSGVVTELPRTGGNSLPYDVNAWRM
Agg5   115 KK---NTGSVVIINGGIISLKEQWVHLVGLFERFDVTVVLTEMPGVGENQLPYNEQSFRM
LobE   115 GLSDGVRRPVMVVSGGIVTVKEAWAPTLAAIRRLGLAGIITEMPGVGENTLPYDRDGWRM
KijE   115 GLSDGVRRPVMLVSGGIVTVKEQWAPTLAAIRRLGMAGIVTEMPGVGENTLPYDEQSWTM
Tmn17  119 GLSAAEPKPVLMVAGGIVSLKEQWAPVTLQAAALGMAIVVTELPGVGENTLPYDREGWRM
AbyA5  176 FGVLLDAVAERADTSRAYALALSFSGHLALRAAPSEPRLRGIVTAGAPVAAFFTDKEWQA
ChlD4  178 LSGILDTVADRARVERTYAMALSFSGHMALRCALDDARLRGVVTVGAPVHDFFTDARWQA
QmnD4  171 IPAILDALG----ADSAYAMMMSFSGHLALRCAARDPRIKGVLTVGAPVAGFFTDAAWQQ
Agg5   172 YSDVLDYLAQDRSDIRCHIFGLSFSGFIAYKNSLTDSRIVGITMAGTPLDSLYHDREVYR
LobE   175 LSHLLDHVSDRADTANAHLLALSFSGHLALRCALEDERIRSVLTAGAPVHDFFTDREWQP
KijE   175 LSRLLDHVADRADVANSHALALSFSGHLAMRCALEDGRIRSVLTAGAPVHDFFTDRDWQA
Tmn17  179 LPALLDAVADRADVSDTYALANSFGGHLALRWAGHDARVRGIVSSGAPVSGFFGDADWLR
AbyA5  236 AVPRVTVDTLARLTQTTP------ATVFDHVRNWALTPQDLAGVRIPVAYVASGRDEIIP
ChlD4  238 RVPRITVDTLARLTDGTP------RHVLGHMADFALGDEQLAALEIPVHYTASLRDEIIP
QmnD4  227 ALPRVTVDTIVHLTGEKP------G----GLADWALSTAELDAIEVPVAYVASKRDEIIP
Agg5   232 RLPYVTRLVIGHNVGKTHPELDNDDKVFGYLDETFVMHQEDINHSVRLYYVQSLRDEVIP
LobE   235 RLPRLTVDSLAQLADDKP------ETVLDRMREWALRPEELRALDIPVRYVACTRDEIIP
KijE   235 ALPRLTVDTLAHLVGEKP------EDALDRLRGWALRPEQLRALDVPVRYVACERDEIIP
Tmn17  239 GVPGITRHTLARLAGAPEG---DDDALHKKIADWALTPAELAGLEIPVRYSTSLRDEIIP
AbyA5  290 PADPALLRTHVRDFRTITHDDVHGSPAHFPHTRLWTLAQVLEMSGADPRHRAAVDGALAQ
ChlD4  292 GSETRRLRDHVRALTLLEHDDVHGAPRHTAETQLWCVRSLLRMEQPRGPRAAV-LDLMWR
QmnD4  277 PQDIELLSAHVRRFSLLEHDDVHGSPAHTAQTGAWLTQSLQAMTAK--------------
Agg5   292 NLEADTIRRLSRQNHIFSLDDVHGSPGYGKTVRVYLLWSLLDSLRLSRVL-HGVAGLGVR
LobE   289 GTDVAMLREHVRDIGVLTHDDVHGAPSHAAETQLWLIRSLVRVVGGKAPVSLV-LGLLHR
KijE   289 GSDVALLREHVRDIEILTHDDVHGAPAHAAETQLWLIRSLLRLRGGKAPTAIT-IGLLYR
Tmn17  296 AGEAAFLQQHVKDLGLNEIDDVHGAPAHVQQTVDWTFGSLLAMRQGLAPS----------
AbyA5  350 VEGGRA------
ChlD4  351 AARARRRLAPRS
QmnD4      ------------
Agg5   351 VLRYLKR-----
LobE   348 LARLRASSAG--
KijE   348 LARLRAAAPG--
Tmn17      ------------
						*	
								*	
								*	
												*	
									*	
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Fig.	S3.	Size	exclusion	chromatography	and	SDS-PAGE	analysis	of	purified	recombinant	wild	
type	 AbyA5,	 SeMet	 labeled	 wild	 type	 AbyA5	 and	 SeMet	 labeled	 AbyA5_QM.	
Chromatograms	 showing	 the	 elution	 profiles	 of	 (A)	 unlabeled	wild	 type	AbyA5,	 (B)	 SeMet	
labeled	wild	 type	 AbyA5,	 and	 (C)	 SeMet	 labeled	 AbyA5_QM,	 from	 a	 Superdex	 200	 16/60	
column	 (GE	Healthcare),	pre-equilibrated	 in	20	mM	Tris-HCl,	150	mM	NaCl,	pH	8.0.	Eluted	
peaks	were	observed	by	monitoring	the	absorbance	of	the	column	eluent	at	280	nm.	Elution	
volumes	are	consistent	with	AbyA5	and	AbyA5_QM	adopting	monomeric	forms	in	solution,	
based	on	comparison	with	the	elution	volumes	of	protein	standards	(Bio-Rad),	analyzed	using	
the	 same	 column	 and	 buffer	 conditions.	 This	 analysis	 was	 performed	 using	 theoretically	
calculated	molecular	masses`	based	on	the	amino	acid	compositions	of	monomeric	wild	type	
AbyA5	 (~43	 kDa;	 pET30	 construct)	 and	AbyA5_QM	 (~41	 kDa;	 pOPINF	 construct),	 including	
vector	encoded	tags	and	linkers.	(D)	SDS-PAGE	analysis	of	unlabeled	wild	type	AbyA5,	SeMet	
labeled	wild	type	AbyA5	and	SeMet	labeled	AbyA5_QM.		
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Figure 57. Chromatogram of AbyA5-SeMet Nickel Affinity Purification. Column eluent was 
monitored at 280 nm. A shaded box denotes the peak corresponding to the elution of 
AbyA5_SeMet. Peak maximum is denoted by a dotted line 
 
Figure 58. Chromatogram of AbyA5-SeMet Size Exclusion Purification. Absorbance of eluent 
was monitored at 280 nm. 
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Figure 63. A Chromatogram Showing Purification of AbyA5_QM via Nickel Affinity 
Chromatography. Column eluent was monitored at 280 nm. A shaded box denotes the peak 
corresponding to the elution of AbyA5_QM. Peak maximum is denoted by a dotted line 
 
 
Figure 64. Chromatogram of AbyA5_QM via Size Exclusion Chromatography. Column eluent 
was monitored at 280 nm. A shaded box denotes the peak corresponding to the elution of 
AbyA5_QM. Peak maximum is denoted by a dotted line 
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Figure 52. Chromatogram of AbyA5 Nickel Affinity Purification. Column eluent was monitored 
at 280 nm. A shaded box denotes the peak corresponding to the elution of AbyA5. Peak maximum 
is denoted by a dotted line 
 
Figure 53. SDS-PAGE Analysis of AbyA5 following Nickel Affinity Purification. Protein 
Marker. Lanes 1-12 show samples of eluent fractions containing protein as determined by 
monitoring U.V. absorbance at 280 nm. Fractions were 2 mL. 10 µl of sample were loaded in each 
case. 
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Figure 52. Chromatogram of AbyA5 Nickel Affinity Purification. Column eluent was monitored 
at 280 nm. A shaded box denotes the peak corresponding to the elution of AbyA5. Peak maximum 
is denoted by a dotted line 
 
Figure 53. SDS-PAGE Analysis of AbyA5 following Nickel Affinity Purification. Protein 
Marker. Lanes 1-12 show samples of eluent fractions containing protein as determined by 
monitoring U.V. absorbance at 280 nm. Fractions were 2 mL. 10 µl of sample were loaded in each 
case. 
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Figure 52. Chromatogram of byA5 Nickel Affi ity P rificatio . Colu n eluent was monitored 
t 280 nm. A shaded box den tes the peak corr spondi g to the elution of AbyA5. Peak maximum 
is denoted by a dotted line 
 
Figure 53. SDS-PAGE Analysis f AbyA5 fo lowing Nickel Aff nity Purification. Protein 
Marker. Lanes 1-12 show samples of elue t fractions co taining p otein as determined by 
monitoring U.V. absorbance at 280 nm. Fractions were 2 L. 10 µl of sample were loaded in each 
case. 
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Figure 54. Chromatogram of AbyA5 Size Exclusion Chromatography. Column eluent was 
monitor d at 280 nm. A shaded box denotes the peak corresponding to the elution of AbyA5. 
Peak maximum is denoted by a dotted line 
 
Figure 55. SDS-PAGE Analysis of AbyA5 following Size Exclusion Chromatography. 
Protein Marker. Lanes 1-13 show samples of eluent ctions correspo ding to th  major peak 
determined by monitoring of eluent absorbance at 280 nm. 10 µl of sample was loaded in each 
case. 
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Figure 63. A Chromatogram Showing Purification of AbyA5_QM via Nickel Affinity 
Chromatography. Column eluent was monitored at 280 nm. A shaded box denotes the peak 
corresponding to the elution of AbyA5_QM. Peak maximum is denoted by a dotted line 
 
 
Figure 64. Chromatogram of AbyA5_QM via Size Exclusion Chromatography. Colum  e uent 
was monitored at 280 nm. A shaded box denotes the peak corresponding to the elution of 
AbyA5_QM. Peak maximum is denoted by a dotted line 
A.	 B.	
C.	 D.	
M	
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Fig	 S4.	 Mass	 spectra	 of	 synthesized	 substrates	 and	 AbyA5	 catalyzed	 reaction	 product.	
Negative	 ion	mode	 ESI	MS	 of	 (R)-9	 and	 (S)-9,	 and	 product	 10	 recovered	 from	 the	 AbyA5	
catalyzed	 acetate	 elimination	 of	 (R)-9	 (see	 fig.	 2).	 Product	masses	 are	 consistent	with	 the	
theoretically	predicted	masses	of	(R)-9	and	(S)-9	(298.14	),	and	product	10	(238.12).		
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Fig.	 S5.	 Size	 exclusion	 chromatography	 and	 circular	 dichroism	 spectra	 of	WT	 and	AbyA5	
point	mutants.	(A)	Chromatograms	showing	the	elution	profiles	of	unlabeled	wild	type	AbyA5,	
H312A	AbyA5,	and	Ser198A	AbyA5	from	a	Superdex	75	16/60	column	(GE	Healthcare),	pre-
equilibrated	 in	20	mM	Tris-HCl,	 150	mM	NaCl,	 pH	8.0.	 (B)	CD	 spectra	of	wild	 type	AbyA5,	
H312A	 AbyA5,	 and	 Ser198A	 AbyA5. CD	 spectra	 were	 collected	 using	 a	 Jasco	 j-1500	
spectropolarimeter	(Jasco,	Tokyo,	Japan)	fitted	with	a	Peltier	temperature	controller.	Spectra	
of	WT	AbyA5	and	mutants	were	collected	from	200	to	250	nm,	using	a	0.5	mm	pathlength	
cuvette,	at	25°C	in	20	mM	sodium	phosphate	and	50	mM	NaCl,	pH	7.5.	The	concentration	of	
each	stock	protein	solution	(∼10	mg/ml)	was	determined	by	absorbance	at	280	nm	followed	
by	dilution	to	0.5	mg/ml	immediately	before	the	experiments.	Final	spectra	were	generated	
as	averages	of	five	repeat	scans,	with	appropriate	protein-free	buffer	spectra	subtracted.	The	
data	were	plotted	without	smoothing	using	Excel.		
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Fig.	S6.	Proposed	catalytic	mechanism	for	acetate	elimination	by	QmnD4.		
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Fig.	S7.	Kinetic	characterization	of	the	AbyA5	catalyzed	hydrolysis	of	p-NPA.	Plot	of	 initial	
velocity/[E]	vs.	substrate	concentration	for	the	AbyA5	catalyzed	hydrolysis	of	p-NPA.	Data	are	
fitted	to	a	rectangular	hyperbola	as	detailed	in	SI	methods.	Values	for	initial	rates	are	mean	
values	calculated	from	three	repeats	of	each	experiment.	Error	bars	are	standard	errors	from	
the	mean.		
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Fig.S8.	Analysis	of	molecular	dynamics	simulations.	A,	Histogram	of	the	distance	between	
SerOG	and	His312	as	observed	between	10-80	ns	in	two	independent	production	simulations	
of	the	apo-enzyme.	This	indicates	that	a	typical	‘catalytic	triad’	alignment	of	these	residues	
occurs	for	~10%	of	the	simulation	time	(hydrogen	bond	occupation:	9.4%).	B,	Histograms	of	
the	His312-Nε2	to	H15	(on	3)	distance	from	2-10	ns	of	two	independent	simulations	for	the	
top	 two	docking	poses	plus	one	additional	docking	pose	 that	displayed	 the	 (next)	 shortest	
initial	 His312-Nε2	 to	H15	 distance.	His312-Nε2	 to	H15	 distances	 of	 the	 docking	 poses	 are	
indicated	by	lines.	Only	3-R	complexes	consistently	maintain	His312-Nε2	to	H15	distances	in	
line	with	proton	abstraction	by	His312	upon	MD	simulation.	(Labels	R1,	R2,	R5	signify	docking	
poses	of	3-R	ranked	1,	2	and	5	with	AutoDock	Vina	predicted	binding	affinities	of	−8.7,	−8.2	
and	−8.1	kcal/mole,	respectively.	Labels	S1,	S2,	S6	signify	docking	poses	of	3-S	ranked	1,	2	and	
5	 with	 AutoDock	 Vina	 predicted	 binding	 affinities	 of	 −8.6,	 −8.5	 and	 −8.2	 kcal/mole,	
respectively.)	
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